Stevanato Group, through Ompi, its specialist in glass primary packaging for the pharmaceutical industry, and SiO2 Medical Products (SMP) jointly announce today a collaboration agreement.
The agreement will enable pharmaceutical and biologics customers, contract filling organizations, and research laboratories to receive SMP's proprietary primary containers in Ompi’s industry-recognized EZ-fill packaging configurations in trays and nest & tubs.
SiO2 Medical Products, a privately-owned company, develops and manufactures precision-molded containers composed of engineered polymers, such as cyclic olefin polymer (COP), and incorporates a thin, transparent, silicon-based coating system composed of organosiloxane and silica nano-layers, which can also incorporate distinct surface properties. This new and patented coating system provides the durability and dimensional consistency of plastics with the oxygen barrier properties, ultra-low extractables, and pH stability of silica glass (i.e., quartz). Bringing together the best qualities of both plastics and glass containers, without their respective drawbacks, presents an innovative approach to primary packaging.
SMP’s primary containers supplied in Ompi’s packaging configurations readily integrate with existing fill-finish processing lines and accelerate the commercialization of pharmaceuticals and biologics. EZ-fill trays and nest & tubs are designed to mitigate the risk of breakages, cosmetic issues, and particulate generation. Validated to be shipped in quantities as low as a single carton, Ompi EZ-fill® offers a solution that can be extended from the clinical trial stage through to industrialization.
"With the agreement with SMP, Ompi further strengthens its EZ-fill® technology leadership and market positioning in secondary packaging,” Andrea Zambon, Marketing Director – Pharmaceutical Systems Division, Stevanato Group, said. “Thanks to our flexible, easy to use, and lean solution, clients can immediately integrate the EZ-fill packaging into their fill-finish lines to commercialize their therapies in the primary container of their choice, now including SMP’s proprietary primary containers.”
"We look forward to working with Ompi to fast-track the packaging, transportation, supply, and integration of SMP’s primary containers with existing fill-finish lines. Ompi’s industry-recognized EZ-fill packaging configurations are often requested by our customers, and we are pleased to collaborate to make that request a reality,” Robert S. Abrams, Founder, CEO and Chairman of SMP, said.